SLU-PP-332 is a research-stage small molecule that activates the estrogen-related receptors ERRα, ERRβ, and ERRγ, with particularly strong activity toward ERRα. It is mainly being investigated as an “exercise mimetic”—a compound intended to reproduce some metabolic adaptations normally produced by aerobic exercise.
1. Exercise-mimetic research
The most prominent application is investigating whether pharmacologically activating ERRs can reproduce exercise-like metabolic responses.
In mice, SLU-PP-332:
- Increased oxidative skeletal-muscle fibers
- Increased mitochondrial activity and cellular respiration
- Activated an ERRα-dependent aerobic-exercise gene program
- Improved endurance/exercise capacity
Potential application: developing future drugs that could reproduce selected metabolic benefits of exercise in people unable to obtain sufficient physical activity.
2. Obesity and fat-loss research
SLU-PP-332 has been investigated in mouse models of obesity. Treatment increased energy expenditure and fatty-acid oxidation, while reducing fat accumulation.
This makes it a research candidate for:
- Obesity
- Excess adiposity
- Abnormal lipid metabolism
- Energy-expenditure disorders
Importantly, these are preclinical applications, not established human treatments.
3. Metabolic syndrome and insulin sensitivity
Studies in obese and ob/ob mice found that SLU-PP-332 improved several metabolic parameters, including glucose handling and insulin sensitivity, while increasing fatty-acid utilization.
Therefore, researchers are investigating ERR activation as a possible future approach for:
- Metabolic syndrome
- Insulin resistance
- Type 2 diabetes
- Abnormal glucose metabolism
4. Mitochondrial and energy-metabolism research
ERRs are important regulators of genes involved in mitochondrial function, oxidative metabolism and fatty-acid utilization. SLU-PP-332 therefore serves as a useful experimental tool for studying how ERR activation changes cellular energy metabolism.
Potential research areas include:
- Mitochondrial dysfunction
- Fatty-acid oxidation
- Oxidative phosphorylation
- Cellular energy expenditure
- Skeletal-muscle metabolic adaptation
5. Skeletal-muscle aging and function
Because SLU-PP-332 can increase oxidative muscle characteristics and endurance in mice, researchers are interested in its possible application to age-related loss of muscle function and physical capacity. The original study specifically proposed ERR targeting as a strategy for improving muscle function during aging.
6. Fatty liver and hepatic metabolism
ERR activation is also being investigated in the context of abnormal lipid accumulation in the liver. In SLU-PP-332-treated obese mouse models, researchers observed reduced hepatic steatosis and changes consistent with increased lipid utilization.
This creates potential research applications for:
- Metabolic dysfunction-associated steatotic liver disease (MASLD)
- Hepatic lipid accumulation
- Abnormal fatty-acid metabolism
7. Drug-discovery and pharmacology research
SLU-PP-332 is particularly valuable as a chemical research tool because it provides a way to experimentally activate all three ERR isoforms and study their contribution to metabolism and exercise physiology.
Researchers can use it to investigate:
- ERRα/β/γ biology
- Exercise-responsive gene expression
- Mitochondrial regulation
- Muscle metabolism
- Metabolic-disease mechanisms
- Development of next-generation ERR agonists
Application overview
| Application | Current evidence | Main purpose |
| Exercise mimetic | Strong preclinical | Reproduce selected exercise-like metabolic effects |
| Obesity | Mouse studies | Increase energy expenditure and reduce adiposity |
| Metabolic syndrome | Mouse studies | Improve metabolic parameters |
| Insulin resistance | Preclinical | Investigate improved glucose/insulin metabolism |
| Mitochondrial function | Cell + animal studies | Increase oxidative metabolism |
| Muscle performance | Mouse studies | Increase oxidative fibers and endurance |
| Aging-related muscle dysfunction | Potential/preclinical | Preserve or improve muscle metabolic capacity |
| Fatty liver | Preclinical | Increase lipid utilization and reduce steatosis |
| Drug discovery | Established research use | Study ERR biology and develop improved agonists |
Important limitation
SLU-PP-332 is not an approved exercise-replacement drug or established human therapy. The major efficacy findings come from cells and animal models, and clinical efficacy and long-term safety in humans remain unestablished. A recent pharmacology review also notes limitations such as poor oral bioavailability and metabolic instability, which complicate its development as a conventional drug.
Interestingly, SLU-PP-332 has also become relevant to anti-doping research because exercise-mimetic compounds can potentially alter endurance and metabolic performance; a 2026 study specifically investigated its metabolites for doping-control purposes.
In short: the major application of SLU-PP-332 is currently research into ERR-driven exercise mimetics and metabolic disease, particularly obesity, insulin resistance, mitochondrial metabolism, skeletal-muscle function, and energy expenditure—not routine supplementation or clinical treatment.